Question · asked by 1 review
Antifibrinolytic therapy (tranexamic acid or epsilon aminocaproic acid) vs placebo/open control: Mean quality of life ‐ health utility
What each review found
Include earlier review versions| Finding | Effect | Studies | GRADE certainty |
|---|---|---|---|
Summary of findings table ‐ Antifibrinolytic drug(s) vs placebo/open control Quality of life (EuroQoL health utility score) · adults with acute spontaneous intracerebral haemorrhage Haemostatic therapies for stroke due to acute, spontaneous intracerebral haemorrhage (2023) · Cochrane Headline outcomes only | no estimate extracted | 2 studies · 2349 participants | High |
Findings are shown side by side, never pooled across reviews.
The reviews
| Review | Searched up to | Included studies | AMSTAR 2 |
|---|---|---|---|
| Haemostatic therapies for stroke due to acute, spontaneous intracerebral haemorrhage 2023 · Cochrane Headline outcomes only | Not reported | list not extracted yet | Not assessed |
Studies behind the findings
None of these reviews ties its included studies to this outcome in the data here. Cochrane reviews and reviews with headline outcomes only do not list their studies yet.
How reviews are matched to this question
Reviews word the same question differently. Four decision models (TypeSafe's Jev, Liquid AI's d1-ultra, SubQ Snap and Baseten's Elephant) judged each wording of the population, intervention, comparator and outcome against the others; two wordings count as the same when at least three of them agree and none clearly disagrees, and findings count as this question only when all four elements match. Timing, setting and subgroup never split a question: they are shown on each finding.